OBJECTIVES: To investigate the impact of the body composition such as skeletal muscle, visceral fat and body mass index (BMI) on patients with resected pancreatic ductal adenocarcinoma (PDAC). METHODS: A total of 265 patients who underwent curative surgery for PDAC were examined in this study. The total skeletal muscle and fat tissue areas were evaluated in a single image obtained at the third lumber vertebra during a preoperative computed tomography (CT) scan. The patients were assigned to either the sarcopenia or non-sarcopenia group based on their skeletal muscle index (SMI) and classified into high visceral fat area (H-VFA) or low VFA (L-VFA) groups. The association of clinicopathological features and prognosis with the body composition were statistically analyzed. RESULTS: There were 170 patients (64.2%) with sarcopenia. The median survival time (MST) was 23.7 months for sarcopenia patients and 25.8 months for patients without sarcopenia. The MST was 24.4 months for H-VFA patients and 25.8 months for L-VFA patients. However, sarcopenia patients with BMI ≥22 exhibited significantly poorer survival than patients without sarcopenia (MST: 19.2 vs. 35.4 months, P = 0.025). There was a significant difference between patients with and without sarcopenia who did not receive chemotherapy (5-year survival rate: 0% vs. 68.3%, P = 0.003). The multivariate analysis revealed that tumor size, positive dissected peripancreatic tissue margin, and sarcopenia were independent prognostic factors. CONCLUSIONS: Sarcopenia is an independent prognostic factor in PDAC patients with a BMI ≥22. Therefore, evaluating skeletal muscle mass may be a simple and useful approach for predicting patient prognosis.
OBJECTIVES: To investigate the impact of the body composition such as skeletal muscle, visceral fat and body mass index (BMI) on patients with resected pancreatic ductal adenocarcinoma (PDAC). METHODS: A total of 265 patients who underwent curative surgery for PDAC were examined in this study. The total skeletal muscle and fat tissue areas were evaluated in a single image obtained at the third lumber vertebra during a preoperative computed tomography (CT) scan. The patients were assigned to either the sarcopenia or non-sarcopenia group based on their skeletal muscle index (SMI) and classified into high visceral fat area (H-VFA) or low VFA (L-VFA) groups. The association of clinicopathological features and prognosis with the body composition were statistically analyzed. RESULTS: There were 170 patients (64.2%) with sarcopenia. The median survival time (MST) was 23.7 months for sarcopeniapatients and 25.8 months for patients without sarcopenia. The MST was 24.4 months for H-VFA patients and 25.8 months for L-VFA patients. However, sarcopeniapatients with BMI ≥22 exhibited significantly poorer survival than patients without sarcopenia (MST: 19.2 vs. 35.4 months, P = 0.025). There was a significant difference between patients with and without sarcopenia who did not receive chemotherapy (5-year survival rate: 0% vs. 68.3%, P = 0.003). The multivariate analysis revealed that tumor size, positive dissected peripancreatic tissue margin, and sarcopenia were independent prognostic factors. CONCLUSIONS:Sarcopenia is an independent prognostic factor in PDAC patients with a BMI ≥22. Therefore, evaluating skeletal muscle mass may be a simple and useful approach for predicting patient prognosis.
Authors: Carla M Prado; Sarah A Purcell; Carolyn Alish; Suzette L Pereira; Nicolaas E Deutz; Daren K Heyland; Bret H Goodpaster; Kelly A Tappenden; Steven B Heymsfield Journal: Ann Med Date: 2018-09-12 Impact factor: 4.709
Authors: Sónia Velho; Maria Pia Costa Santos; Cátia Cunha; Lisa Agostinho; Rita Cruz; Filipe Costa; Mafalda Garcia; Paulo Oliveira; Rui Maio; Vickie E Baracos; Marília Cravo Journal: GE Port J Gastroenterol Date: 2020-05-19
Authors: Linda B M Weerink; Anouk van der Hoorn; Barbara L van Leeuwen; Geertruida H de Bock Journal: J Cachexia Sarcopenia Muscle Date: 2020-03-03 Impact factor: 12.910
Authors: Cynthia Stretch; Jean-Michel Aubin; Beata Mickiewicz; Derek Leugner; Tariq Al-Manasra; Elizabeth Tobola; Santiago Salazar; Francis R Sutherland; Chad G Ball; Elijah Dixon; Hans J Vogel; Sambasivario Damaraju; Vickie E Baracos; Oliver F Bathe Journal: PLoS One Date: 2018-05-03 Impact factor: 3.240